Investors don't buy Immunicum line on trial failure

30 August 2019

Immunicum (STO: IMMU) failed to show superiority in 18-month survival rates by adding its off-the-shelf cell therapy ilixadencel to Pfizer’s (NYSE: PFE) Sutent (sunitinib) in metastatic renal cell carcinoma, according to Phase II results.

But the Swedish biotech company claimed that the most relevant results from the trial were those showing that the ilixadencel and Sutent combination arm achieved complete tumor responses in five out of 45 evaluable metastatic patients, compared to one out of 25 in the monotherapy group.

Immunicum shares closed down by 14% on Thursday, and they were down by nearly as much again at lunchtime on Friday, suggesting that markets were not convinced by the company’s line.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK